IDNA - ETF AI Analysis
Top Page
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The fund has shown strong gains so far this year and in recent months, indicating positive momentum in its strategy.
Leading Health Care Innovators
Several top holdings, including companies focused on genomics and advanced medicines, have delivered strong year-to-date performance that supports the ETF’s returns.
Global Health Care Exposure
While most holdings are in the U.S., the fund also invests in health care companies from Europe and Asia, adding some international diversification.
Negative Factors
High Sector Concentration
With most assets in health care, the ETF is heavily exposed to swings in one industry rather than spread across many sectors.
Meaningful Single-Stock Weights
Several individual companies each make up a noticeable share of the portfolio, which increases the impact if any one of them runs into problems.
Moderate Expense Ratio
The fund’s fees are not extremely high but are significant enough that they can slightly reduce long-term returns compared with very low-cost broad market ETFs.
IDNA vs. SPDR S&P 500 ETF (SPY)
AUM197.81M
RegionGlobal
Expense Ratio0.47%
Beta0.90
IssueriShares
Inception DateJun 11, 2019
Dividend Yield0.87%
Asset ClassEquity
Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume26,718
30 Day Avg. Volume47,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.82Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDNA Summary
IDNA is an ETF that follows the NYSE FactSet Global Genomics and Immuno Biopharma Index, focusing on companies using genetics and immune system research to improve healthcare. It holds firms working on gene editing, genome sequencing, and advanced treatments, including well-known names like Moderna and Bayer. Investors might consider IDNA if they want growth potential from cutting-edge medical innovations and global diversification within the healthcare sector. However, this fund is heavily focused on genomics and biotech, so its price can be very volatile and may go up or down sharply with changes in the healthcare and biotech markets.
How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.
What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.
IDNA Top 10 Holdings
IDNA is very much a genomics and biotech story, with performance driven by a handful of high‑beta names. Twist Bioscience and Revolution Medicines have been rising over the past few months, giving the fund some upside juice, while Moderna has been losing steam lately and acting as a bit of a drag despite its longer-term rebound. Steadier big pharma players like Merck, Roche, and Takeda help smooth out the ride, but they don’t fully offset the volatility from smaller, more experimental names. Overall, it’s a globally diversified but sector‑concentrated bet on cutting‑edge healthcare.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Twist Bioscience | 5.51% | $10.90M | $5.70B | 351.13% | 43 Neutral | |
| Bayer | 4.80% | $9.49M | €47.21B | 95.25% | 54 Neutral | |
| Revolution Medicines | 4.64% | $9.17M | $39.87B | 486.14% | 52 Neutral | |
| Regeneron | 4.25% | $8.41M | $79.94B | 39.32% | 78 Outperform | |
| ― | 4.20% | $8.30M | ― | ― | ― | |
| Incyte | 4.05% | $8.00M | $24.23B | 53.80% | 81 Outperform | |
| Moderna | 3.97% | $7.85M | $21.75B | 126.53% | 59 Neutral | |
| Takeda Pharmaceutical Co | 3.88% | $7.67M | ¥8.80T | 20.41% | 66 Neutral | |
| Roche Holding AG | 3.82% | $7.55M | $348.49B | 51.05% | 73 Outperform | |
| Vertex Pharmaceuticals | 3.79% | $7.49M | $121.09B | 35.34% | 78 Outperform |
IDNA Technical Analysis
Positive
―
Price Trends
31.86
Positive
30.61
Positive
29.01
Positive
Market Momentum
0.37
Negative
68.38
Neutral
89.96
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.76, equal to the 50-day MA of 31.86, and equal to the 200-day MA of 29.01, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 68.38 is Neutral, neither overbought nor oversold. The STOCH value of 89.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.
IDNA Peer Comparison
Comparison Results
Performance Comparison
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
34.78
13.94
66.89%
GII
SPDR S&P Global Infrastructure ETF
―
―
―
MGNR
American Beacon GLG Natural Resources ETF
―
―
―
ROBT
First Trust Nasdaq Artificial Intelligence & Robotics ETF
―
―
―
WTAI
WisdomTree Artificial Intelligence and Innovation Fund
―
―
―
UFO
Procure Space ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents